|
57 Products |
| 57 Products |
|
190 Diseases |  |
10960 News |  |
| «12345678910111213...105106» |
- Zeposia (ozanimod) / BMS
Whole Brain, Cortical Grey Matter, and Thalamic Volume Changes During 5 (Posters) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_1267;
- Zeposia (ozanimod) / BMS
Safety Patterns Over up to 8 Years With Ozanimod in Patients with Relapsing Multiple Sclerosis: Final Results From the DAYBREAK Open-label Extension Study (Posters) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_1254;
- Zeposia (ozanimod) / BMS
Update on Long-term Safety and Tolerability of Ozanimod by Age Category in Patients With Relapsing Multiple Sclerosis: Final Data From an Open-Label Extension Study (Posters) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_1252;
- Zeposia (ozanimod) / BMS
Absolute Lymphocyte Count Around Infections During Phase 3 and Open-Label Extension Trials of Ozanimod in Participants With Relapsing Multiple Sclerosis: Final Results From the DAYBREAK Open-label Extension Study (Posters) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_1251;
- Zeposia (ozanimod) / BMS
Impact of Ozanimod on Absolute Lymphocyte Count Stability and Recovery Over Time in Participants With Relapsing Multiple Sclerosis: Final Results From the DAYBREAK Open-label Extension Study (Posters) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_1233;
- Mayzent (siponimod) / Novartis
Progressive multifocal leukoencephalopathy in a patient treated with siponimod for secondary progressive multiple sclerosis (D3) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_1227;
- Mayzent (siponimod) / Novartis
Siponimod reduces proinflammatory activation of microglia in in vitro and in vivo models of multiple sclerosis and enables neuroprotection (Posters) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_1152;
- Zeposia (ozanimod) / BMS
Association of Baseline Spinal Cord Area and Brain Volume With Long-Term Disability Progression in Ozanimod-Treated Participants With Relapsing Multiple Sclerosis: Final Analysis From the DAYBREAK Open-label Extension Study (Posters) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_882;
- Tysabri (natalizumab) / Biogen, Royalty
Development of cerebral oxygen consumption over time in RRMS patients after treatment with natalizumab or fingolimod (Posters) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_859;
- fingolimod / Generic mfg.
Fingolimod, cognition and MRI: a longitudinal study (Posters) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_581;
- Mayzent (siponimod) / Novartis
Treatment satisfaction and quality of life of SPMS Patients Treated with Siponimod in Germany (Posters) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_480;
- fingolimod / Generic mfg.
Sex-Based Disparities in Disease Reactivation After Fingolimod Cessation: Insights from Preclinical and Clinical Investigations (D3) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_440;
- fingolimod / Generic mfg.
Pulmonary cryptococcosis in association with fingolimod treatment in a patient with MS: a clinical case report and review of the literature. (Posters) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_277;
- fingolimod / Generic mfg.
Specific T-cell responses to Varicella Zoster Virus glycoprotein E are impaired in people with multiple sclerosis receiving fingolimod (Posters) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_250;
- Zeposia (ozanimod) / BMS
T cell recall response and SARS-Cov2 breakthrough infections in patients treated with ozanimod (D3) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_219;
- | Rituxan (rituximab) / Roche
Journal: Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study. (Pubmed Central) - Jul 6, 2024
Accumulated dose and time on rituximab treatment are associated with a modest but significant decline in immunoglobulin levels. Previous MS therapies may influence additional IgG decline.
- | fingolimod / Generic mfg.
Journal: Investigation of fingolimod-induced lymphocyte sequestration on inflammatory response and neurological damages after cardiac arrest. (Pubmed Central) - Jul 2, 2024
Previous MS therapies may influence additional IgG decline. Fingolimod-induced WBC sequestration, and more specifically lymphocytes sequestration, did not improve clinical neurological dysfunction following cardiac arrest although it reduced cerebral infiltration by lymphocytes.
- || icanbelimod (CBP-307) / Suzhou Connect Biopharma
Clinical, PK/PD data, Journal: Icanbelimod (CBP-307), a next-generation Sphingosine-1-phosphate receptor modulator, in healthy men: pharmacokinetics, pharmacodynamics, safety, and tolerability in a randomized trial in Australia. (Pubmed Central) - Jul 2, 2024
P1
Icanbelimod was well-tolerated up to 0.5 mg and effectively reduced lymphocyte counts. ClinicalTrials.gov, identifier NCT02280434.b.
- | fingolimod / Generic mfg.
Journal: Multiple sclerosis in Central America and Caribbean countries: frequency and clinical characterization of an emergent disease. (Pubmed Central) - Jul 2, 2024
Common initial therapies were interferon and fingolimod...This is the first study providing data on frequencies and clinical characteristics from 8 countries from the Central American and Caribbean region, addressing MS as an emergent epidemiologic disorder. More studies from these areas are encouraged.
- Zeposia (ozanimod) / BMS
Switch from fingolimod to ozanimod for safety or intolerance reasons (B5) - Jul 2, 2024 - Abstract #EAN2024EAN_2956;
More studies from these areas are encouraged. Switching from fingolimod to ozanimod might be a good strategy in patients who experienced lymphopenia or hypertransaminasemia during fingolimod therapy.
- Zeposia (ozanimod) / BMS
OzEAN interim analysis: treatment satisfaction, QoL, and fatigue in RRMS patients after 1-year ozanimod use in Germany (B6) - Jul 2, 2024 - Abstract #EAN2024EAN_2843;
P
Switching from fingolimod to ozanimod might be a good strategy in patients who experienced lymphopenia or hypertransaminasemia during fingolimod therapy. This interim analysis indicates a positive effect of ozanimod on patient QoL and fatigue, along with high treatment satisfaction.
- Lemtrada (alemtuzumab) / Sanofi
Alemtuzumab in Relapsing-remitting Multiple Sclerosis: Navigating Efficacy and Autoimmune Challenges (B6) - Jul 2, 2024 - Abstract #EAN2024EAN_2842;
Despite lacking specific risk factors for alemtuzumabassociated thyroid eye disease, except gender, the patient proved unresponsive to immunosuppression, necessitating thyroidectomy. This case highlights alemtuzumab's efficacy in RRMS while underscoring the need for monitoring due to potential autoimmune complications, with a favorable clinical outcome despite challenges.
- Zeposia (ozanimod) / BMS
Long-term Outcomes with Ozanimod in the DAYBREAK Extension Trial by Number of MS Relapses During the Phase 3 Trials (B5) - Jul 2, 2024 - Abstract #EAN2024EAN_2839;
P3
This case highlights alemtuzumab's efficacy in RRMS while underscoring the need for monitoring due to potential autoimmune complications, with a favorable clinical outcome despite challenges. Regardless of prior relapse trends in phase 3 trials, longterm treatment with ozanimod for up to 60?months in DAYBREAK was associated with clinical and radiologic improvement.
- Zeposia (ozanimod) / BMS
Final Analysis of Long-term Hepatic Safety of Ozanimod in an Open-Label Extension Trial of Relapsing Multiple Sclerosis (B5) - Jul 2, 2024 - Abstract #EAN2024EAN_2836;
P3
Regardless of prior relapse trends in phase 3 trials, longterm treatment with ozanimod for up to 60?months in DAYBREAK was associated with clinical and radiologic improvement. After up to nearly 7?years of ozanimod in DAYBREAK (mean 60.9?months), ALT and AST elevations ?3
- Zeposia (ozanimod) / BMS
8-Point Change in Symbol Digit Modalities Test Scores: Findings From the Phase 3 SUNBEAM and DAYBREAK Ozanimod Trials (B5) - Jul 2, 2024 - Abstract #EAN2024EAN_2833;
P3
Long-term ozanimod treatment protects from cognitive deterioration. These data support the early use of ozanimod in patients with RMS.
- Tysabri (natalizumab) / Biogen, Royalty
Liver injury in patients with multiple sclerosis: a case series (B5) - Jul 2, 2024 - Abstract #EAN2024EAN_2604;
Vigilant monitoring and a multidisciplinary approach are fundamental. Liver biopsy can contribute in differential diagnosis and informing therapeutic decisions.
- Ocrevus (ocrelizumab) / Roche
Ocrelizumab-induced colitis in patients with multiple sclerosis: an emerging safety issue (B5) - Jul 2, 2024 - Abstract #EAN2024EAN_2601;
FDA recently issued a warning regarding OAC, which could be potentially severe. We highlight the importance for clinicians of being aware of this safety risk and of a prompt intervention with multidisciplinary approach, including endoscopic evaluation and timely treatment.
- Zeposia (ozanimod) / BMS, Ponvory (ponesimod) / Juvise Pharma, Vanda, Mayzent (siponimod) / Novartis
Comparing Lymphocyte Count among different S1P modulators in Multiple Sclerosis: a Multicenter Real-World Study (B6) - Jul 2, 2024 - Abstract #EAN2024EAN_2488;
Our study aims to compare the absolute lymphocytes counts (ALCs) of MS patients treated with Fingolimod (FTY), Siponimod (SIP), Ozanimod (OZA), and Ponesimod (PON). Despite a short follow-up, our study demonstrated a different degree of induced-lymphopenia among S1P modulators, as OZA and PON showed higher ALCs and a lower percentage of severe lymphopenia in pwMS.
- Ocrevus (ocrelizumab) / Roche, Mayzent (siponimod) / Novartis
Ocrelizumab versus siponimod: a real life comparison study (B6) - Jul 2, 2024 - Abstract #EAN2024EAN_2487;
Despite a short follow-up, our study demonstrated a different degree of induced-lymphopenia among S1P modulators, as OZA and PON showed higher ALCs and a lower percentage of severe lymphopenia in pwMS. Despite a short 18-month follow-up, similar treatment outcomes in elderly paMS patients in SIP or OCR therapy suggest that both treatments are similarly effective and safe in elderly patients.
- Tysabri (natalizumab) / Biogen, Royalty
Analysis of MS patients treated with natalizumab or fingolimod- 5 year observational study (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_1991;
- Mayzent (siponimod) / Novartis
The possibilities of using siponimod for patients with multiple sclerosis and older than 65 years (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_1961;
- Mayzent (siponimod) / Novartis
Single center experience using siponimod in active SPMS (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_1934;
- Mayzent (siponimod) / Novartis
Siponimod from fingolimod direct switch in patients transitioning in secondary progressive multiple sclerosis (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_1648;
- Zeposia (ozanimod) / BMS
An atypical case of macular oedema in ozanimod (B5) - Jul 2, 2024 - Abstract #EAN2024EAN_973;
This case highlights the risk of developing ME during ozanimod exposure. Further research is needed to better understand whether a long term exposition to different S1PR, with different drug sequencing, may be associated with higher risk of ME.
- Mayzent (siponimod) / Novartis
Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications (B5) - Jul 2, 2024 - Abstract #EAN2024EAN_972;
Further research is needed to better understand whether a long term exposition to different S1PR, with different drug sequencing, may be associated with higher risk of ME. Patients treated with siponimod showed a T and B lymphocyte reduction, especially CD4+, CD3+CD20+, na
- || fingolimod / Generic mfg.
Review, Journal: Cryptococcosis Associated With Biologic Therapy: A Narrative Review. (Pubmed Central) - Jul 1, 2024
antagonists, Bruton tyrosine kinase inhibitors, fingolimod, JAK/STAT inhibitors (Janus kinase/signal transducer and activator of transcription), and monoclonal antibody against CD52. Other risk factors-such as age, underlying condition, and concurrent immunosuppressants, especially corticosteroids-should also be taken into account during risk stratification.
- | fingolimod / Generic mfg., azathioprine / Generic mfg.
Journal, Real-world evidence, Machine learning, Real-world: Use of Real-World Data and Machine Learning to Screen for Maternal and Paternal Characteristics Associated with Cardiac Malformations. (Pubmed Central) - Jul 1, 2024
Signals identified might be explained by confounding, measurement error, and selection bias and warrant further investigation. The screening methods employed identified known risk factors, suggesting potential utility for identifying novel risk factors for other pregnancy outcomes.
- || Mayzent (siponimod) / Novartis
PK/PD data, Preclinical, Journal: In Vivo Ocular Pharmacokinetics and Toxicity of Siponimod in Albino Rabbits. (Pubmed Central) - Jul 1, 2024
This study provides important information necessary for the formulation and development of siponimod for ophthalmologic applications. The short half-life of siponimod necessitates the development of a sustained drug delivery system to maintain therapeutic concentrations over an extended period, while the lack of short-term ocular toxicity observed in the retinas of siponimod-treated rabbits supports possible clinical use.
- | fingolimod / Generic mfg.
Journal, Immune cell: Corticosteroid-depending effects on peripheral immune cell subsets vary according to disease modifying strategies in multiple sclerosis. (Pubmed Central) - Jun 28, 2024
The short half-life of siponimod necessitates the development of a sustained drug delivery system to maintain therapeutic concentrations over an extended period, while the lack of short-term ocular toxicity observed in the retinas of siponimod-treated rabbits supports possible clinical use. We compared the impact of an IVMP treatment on a broad variety of immune cell subsets within three groups: twelve patients who were treatment-na
- | fingolimod / Generic mfg.
Journal: Liquid chromatography-tandem mass spectrometry for determination of fingolimod and its active metabolite fingolimod phosphate in whole blood of patients with multiple sclerosis. (Pubmed Central) - Jun 27, 2024
The coefficients of variation for fingolimod phosphate were in the range of 2.73-9.31%, and the recovery was 90.08-107.00%. The method is quite easy and fast and can be used for routine analysis.
- ||||| Zeposia (ozanimod) / BMS
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, HEOR: OzEAN: A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia (clinicaltrials.gov) - Jun 26, 2024
P=N/A, N=450, Active, not recruiting, Sponsor: Bristol-Myers Squibb
The method is quite easy and fast and can be used for routine analysis. Recruiting --> Active, not recruiting | N=1300 --> 450 | Trial completion date: Nov 2029 --> Nov 2027 | Trial primary completion date: Mar 2029 --> Mar 2027
- | fingolimod / Generic mfg.
Trial completion: FITCH: Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage (clinicaltrials.gov) - Jun 26, 2024
P1, N=28, Completed, Sponsor: Wake Forest University Health Sciences
Recruiting --> Active, not recruiting | N=1300 --> 450 | Trial completion date: Nov 2029 --> Nov 2027 | Trial primary completion date: Mar 2029 --> Mar 2027 Active, not recruiting --> Completed
- ||| vibozilimod (SCD-044) / Sun Pharma
Enrollment closed: SOLARES-AD-1: To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Jun 26, 2024
P2, N=238, Active, not recruiting, Sponsor: Sun Pharmaceutical Industries Limited
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Velsipity (etrasimod) / Pfizer
Enrollment closed: ELEVATE UC OLE: An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - Jun 26, 2024
P3, N=772, Active, not recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| cenerimod (ACT-334441) / Viatris
New P3 trial: OPUS OLE: Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus (clinicaltrials.gov) - Jun 25, 2024
P3, N=680, Not yet recruiting, Sponsor: Idorsia Pharmaceuticals Ltd.
- | fingolimod / Generic mfg.
Retrospective data, Journal: A two-years real-word study with fingolimod: early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression. (Pubmed Central) - Jun 24, 2024
MS patients that are male, older, and with a low clinical and radiological activity at fingolimod initiation have a greater probability to reach NEDA-3 condition after two years with this therapy. An intriguing association of EBV with the progression of the disease has also been described, but it should be further study in a larger cohort to confirm these results.
- | Mayzent (siponimod) / Novartis, S1PR agonist / Boehringer Ingelheim
Journal: Re-emergence of T lymphocyte-mediated synaptopathy in progressive multiple sclerosis. (Pubmed Central) - Jun 24, 2024
Transition from RRMS to SPMS involves the reappearance of T cell-mediated synaptotoxicity. Siponimod counteracts T cell-induced excitotoxicity, emphasizing the significance of inflammatory synaptopathy in progressive MS and its potential as a promising pharmacological target.
- Zeposia (ozanimod) / BMS
Trial initiation date: Ulcerative Colitis Leukocyte TRAfficking After Treatment With Zeposia: the ULTRAZ Study (clinicaltrials.gov) - Jun 24, 2024
P4, N=12, Not yet recruiting, Sponsor: Geert D'Haens
Siponimod counteracts T cell-induced excitotoxicity, emphasizing the significance of inflammatory synaptopathy in progressive MS and its potential as a promising pharmacological target. Initiation date: Mar 2024 --> Aug 2024
- Velsipity (etrasimod) / Pfizer
The Efficacy and Safety of Etrasimod for Induction Therapy in China Subjects with Moderately to Severely Active Ulcerative Colitis: Results of ES101002 Study Induction Period () - Jun 22, 2024 - Abstract #AOCC2024AOCC_341;
- Zeposia (ozanimod) / BMS
Ozanimod as induction and maintenance therapy for ulcerative colitis: A randomized, double-blind, placebo- controlled study in Japan (J-True North) (Grand Ballroom 3) - Jun 22, 2024 - Abstract #AOCC2024AOCC_198;